|
|
|
|
|
|
|
|
|
|
Super Quote | Detail Quote | Interactive Chart | Transaction | Related News | Related Securities | Company Information | Dividend Records | Short Sell
01877 JUNSHI BIO
Nominal 
18.220 +0.110 (+0.607%) | 2026/06 - Interim RMB(K¥) | %Chg (Compare to Interim) | 2025/12 RMB(K¥) | 2024/12 RMB(K¥) | 2023/12 RMB(K¥) | 2022/12 RMB(K¥) | |
| Turnover | 1,696,211 | 45.176% | 2,498,420 | 1,948,317 | 1,502,550 | 1,453,493 |
| Cost of Sales | (416,780) | 70.561% | (522,756) | (498,861) | (667,290) | (526,282) |
| Gross Profit | 1,279,431 | 38.463% | 1,975,664 | 1,449,456 | 835,260 | 927,211 |
| 2026/06 - Interim RMB(K¥) | %Chg (Compare to Interim) | 2025/12 RMB(K¥) | 2024/12 RMB(K¥) | 2023/12 RMB(K¥) | 2022/12 RMB(K¥) | ||
| Change in FV & Impairment on Inv. Prop. | -- | -- | -- | -- | -- | -- | |
| Change in FV & Impairment on Others | (4,110) | -- | 3,359 | 19,726 | (23,484) | (47) | |
| Profit / (Loss) on Disposal | -- | -- | -- | -- | -- | -- | |
| Other Non-operating Items | -- | -- | -- | -- | -- | -- | |
| Share of Results of Asso. & JCEs | (43,205) | 71.387% | (116,102) | (35,026) | (60,484) | (71,032) | |
| Profit / (Loss) before Taxation | (29,542) | -93.921% | (986,574) | (1,359,028) | (2,489,887) | (2,675,202) | |
| Taxation | (7,444) | -- | 13,881 | (22,552) | (43,995) | 93,107 | |
| Profit / (Loss) from Discontinued Operations | -- | -- | -- | -- | -- | -- | |
| Non-controlling Interests | 62,487 | 17.949% | 131,783 | 99,182 | 252,258 | 196,028 | |
| Others | -- | -- | -- | -- | -- | -- | |
| Profit / (Loss) Attributable to Shareholders | 25,501 | -- | (840,910) | (1,282,398) | (2,281,624) | (2,386,067) | |
| 2026/06 - Interim RMB(K¥) | %Chg (Compare to Interim) | 2025/12 RMB(K¥) | 2024/12 RMB(K¥) | 2023/12 RMB(K¥) | 2022/12 RMB(K¥) | |
| Net Finance Costs / (Income) | 57,248 | 47.943% | 42,887 | 7,722 | (70,420) | (31,648) |
| Depreciation & Amortisation | 157,637 | -3.472% | 323,797 | 328,552 | 303,220 | 263,907 |
| Directors' Emoluments | -- | -- | -- | 40,585 | 55,345 | 68,691 |
| 2026/06 - Interim | %Chg (Compare to Interim) | 2025/12 | 2024/12 | 2023/12 | 2022/12 | |
| Auditor's Opinion Status | N/A | -- | Unqualified | Unqualified | Unqualified | Unqualified |
Market Valuation Indicators
| 2026/06 - Interim | %Chg (Compare to Interim) | 2025/12 | 2024/12 | 2023/12 | 2022/12 | |
| EPS (cts) | 2.000 | -- | -84.000 | -130.000 | -232.000 | -260.000 |
| DPS (cts) | 0.000 | -- | 0.000 | 0.000 | 0.000 | 0.000 |
| Dividend Payout Ratio (%) | -- | -- | -- | -- | -- | -- |
| Cash flow per share ($) | -- | -- | (0.511) | (1.465) | (2.045) | (1.935) |
| NBV per share ($) | 5.809 | -- | 5.895 | 5.969 | 7.275 | 9.667 |
| Remarks: | Real time quote last updated: 04/09/2026 17:59 |
| Real-time basic market prices of Hong Kong securities are provided by HKEx; a Designated Website authorized by the HKEx Group to provide the Service. | |
| Profit / (Loss) Attributable to Shareholders (K¥) | RMB 25,501 |
| %Change | -- |
| EPS / (LPS) | RMB 0.020 |
| NBV Per Share (¥) | RMB 5.809 |